

Tari A King

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8905409/publications.pdf>

Version: 2024-02-01

151
papers

11,065
citations

117625

34
h-index

32842

100
g-index

155
all docs

155
docs citations

155
times ranked

20454
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumour exosome integrins determine organotropic metastasis. <i>Nature</i> , 2015, 527, 329-335.	27.8	3,688
2	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. <i>Nature</i> , 2016, 534, 47-54.	27.8	1,760
3	Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. <i>Cell</i> , 2015, 163, 506-519.	28.9	1,485
4	Clinical Management Factors Contribute to the Decision for Contralateral Prophylactic Mastectomy. <i>Journal of Clinical Oncology</i> , 2011, 29, 2158-2164.	1.6	298
5	How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 3467-3474.	1.5	232
6	Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 335-343.	27.6	164
7	Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. <i>Journal of Clinical Oncology</i> , 2015, 33, 3945-3952.	1.6	153
8	In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. <i>Nature Genetics</i> , 2015, 47, 1212-1219.	21.4	139
9	Skin Flap Necrosis After Mastectomy With Reconstruction: A Prospective Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 257-264.	1.5	121
10	The Genomic Landscape of Male Breast Cancers. <i>Clinical Cancer Research</i> , 2016, 22, 4045-4056.	7.0	119
11	Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 2416-2427.	1.6	112
12	Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples. <i>Nature Medicine</i> , 2017, 23, 376-385.	30.7	111
13	Heterogenic Loss of the Wild-Type BRCA Allele in Human Breast Tumorigenesis. <i>Annals of Surgical Oncology</i> , 2007, 14, 2510-2518.	1.5	82
14	Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC) Tj ETQq0 0 0.5gBT /Overlock 10 T	1.5	82
15	Developing a Service Model That Integrates Palliative Care Throughout Cancer Care: The Time Is Now. <i>Journal of Clinical Oncology</i> , 2014, 32, 3330-3336.	1.6	80
16	A Prospective Analysis of the Effect of Blue-Dye Volume on Sentinel Lymph Node Mapping Success and Incidence of Allergic Reaction in Patients With Breast Cancer. <i>Annals of Surgical Oncology</i> , 2004, 11, 535-541.	1.5	67
17	Is pleomorphic lobular carcinoma really a distinct clinical entity?. <i>Journal of Surgical Oncology</i> , 2008, 98, 314-317.	1.7	63
18	Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 3502-3509.	1.5	61

#	ARTICLE	IF	CITATIONS
19	Is there a role for routine screening MRI in women with LCIS?. Breast Cancer Research and Treatment, 2013, 142, 445-453.	2.5	53
20	Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events. Cancer, 2004, 101, 926-933.	4.1	52
21	Increased Progesterone Receptor Expression in Benign Epithelium of BRCA1-Related Breast Cancers. Cancer Research, 2004, 64, 5051-5053.	0.9	51
22	Preoperative Psychosocial and Psychophysical Phenotypes as Predictors of Acute Pain Outcomes After Breast Surgery. Journal of Pain, 2019, 20, 540-556.	1.4	51
23	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. JAMA Oncology, 2020, 6, 505.	7.1	51
24	Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. JAMA Oncology, 0, , .	7.1	51
25	SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. Npj Breast Cancer, 2019, 5, 16.	5.2	48
26	Cadherinâ€“catenin complex dissociation in lobular neoplasia of the breast. Breast Cancer Research and Treatment, 2012, 132, 641-652.	2.5	47
27	Margins in Breast-Conserving Surgery After Neoadjuvant Therapy. Annals of Surgical Oncology, 2018, 25, 3541-3547.	1.5	47
28	Lobular Carcinomas <i>In Situ</i> Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma. Clinical Cancer Research, 2019, 25, 674-686.	7.0	44
29	Can magnetic resonance imaging be used to select patients for sentinel lymph node biopsy in prophylactic mastectomy?. Cancer, 2008, 112, 1214-1221.	4.1	43
30	Biâ€“allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. Journal of Pathology, 2017, 242, 165-177.	4.5	43
31	Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships. Molecular Oncology, 2016, 10, 360-370.	4.6	41
32	Evaluation of Local and Distant Recurrence Patterns in Patients with Triple-Negative Breast Cancer According to Age. Annals of Surgical Oncology, 2017, 24, 698-704.	1.5	39
33	Contemporary Multi-Institutional Cohort of 550 Cases of Phyllodes Tumors (2007-2017) Demonstrates a Need for More Individualized Margin Guidelines. Journal of Clinical Oncology, 2021, 39, 178-189.	1.6	39
34	Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. Breast Cancer Research, 2012, 14, R103.	5.0	38
35	Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review. Breast Cancer Research and Treatment, 2017, 165, 411-420.	2.5	38
36	Contralateral breast cancers: Independent cancers or metastases?. International Journal of Cancer, 2018, 142, 347-356.	5.1	37

#	ARTICLE	IF	CITATIONS
37	Lobular Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 81-94.	1.5	36
38	Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2019, 26, 55-61.	1.5	36
39	Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2017, 24, 2509-2517.	1.5	35
40	Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 587-596.	2.5	33
41	Insulin resistance contributes to racial disparities in breast cancer prognosis in US women. <i>Breast Cancer Research</i> , 2020, 22, 40.	5.0	33
42	Occult Malignancy in Patients Undergoing Contralateral Prophylactic Mastectomy. <i>Annals of Surgery</i> , 2011, 254, 2-7.	4.2	32
43	Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion. <i>Molecular Oncology</i> , 2015, 9, 772-782.	4.6	32
44	Clonal relationships between lobular carcinoma in situ and other breast malignancies. <i>Breast Cancer Research</i> , 2016, 18, 66.	5.0	32
45	Prediction of Persistent Pain Severity and Impact 12 Months After Breast Surgery Using Comprehensive Preoperative Assessment of Biopsychosocial Pain Modulators. <i>Annals of Surgical Oncology</i> , 2021, 28, 5015-5038.	1.5	31
46	Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis. <i>Annals of Surgical Oncology</i> , 2019, 26, 3517-3525.	1.5	29
47	The Tyrer&Cuzick Model Inaccurately Predicts Invasive Breast Cancer Risk in Women With LCIS. <i>Annals of Surgical Oncology</i> , 2020, 27, 736-740.	1.5	29
48	Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1358-1367.	1.5	29
49	Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach. <i>Annals of Surgical Oncology</i> , 2019, 26, 4326-4336.	1.5	28
50	Lobular Neoplasia. <i>Surgical Oncology Clinics of North America</i> , 2014, 23, 487-503.	1.5	27
51	Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 35.	5.2	27
52	The Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In Situ in Patients with Intraductal Papilloma without Atypia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 034). <i>Annals of Surgical Oncology</i> , 2021, 28, 2573-2578.	1.5	27
53	Surgeon Variability and Factors Predicting for Reoperation Following Breast-Conserving Surgery. <i>Annals of Surgical Oncology</i> , 2018, 25, 2573-2578.	1.5	26
54	Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer. <i>Journal of the American College of Surgeons</i> , 2020, 231, 434-447e2.	0.5	24

#	ARTICLE	IF	CITATIONS
55	Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 227-241.	0.8	24
56	Alcohol consumption and breast tumor gene expression. <i>Breast Cancer Research</i> , 2017, 19, 108.	5.0	23
57	Patterns of axillary evaluation in older patients with breast cancer and associations with adjuvant therapy receipt. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 555-566.	2.5	23
58	American Registry of Pathology Expert Opinions: The Spectrum of Lobular Carcinoma in Situ: Diagnostic Features and Clinical Implications. <i>Annals of Diagnostic Pathology</i> , 2020, 45, 151481.	1.3	23
59	Neoadjuvant Endocrine Therapy in Clinical Practice. <i>JAMA Oncology</i> , 2021, 7, 1700.	7.1	23
60	RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF- κ B activation and EGFR signaling. <i>Oncogene</i> , 2018, 37, 5101-5114.	5.9	22
61	Evaluation of Breast and Axillary Lymph Node Specimens in Breast Cancer Patients Treated With Neoadjuvant Systemic Therapy. <i>Advances in Anatomic Pathology</i> , 2019, 26, 221-234.	4.3	22
62	Development and Validation of the BREAST-Q Breast-Conserving Therapy Module. <i>Annals of Surgical Oncology</i> , 2020, 27, 2238-2247.	1.5	22
63	Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy. <i>Breast</i> , 2022, 63, 123-139.	2.2	22
64	De-escalating axillary surgery in early-stage breast cancer. <i>Breast</i> , 2022, 62, S43-S49.	2.2	22
65	Is There a Low-Grade Precursor Pathway in Breast Cancer?. <i>Annals of Surgical Oncology</i> , 2012, 19, 1115-1121.	1.5	20
66	Impact of Age on Locoregional and Distant Recurrence After Mastectomy for Ductal Carcinoma In Situ With or Without Microinvasion. <i>Annals of Surgical Oncology</i> , 2019, 26, 4264-4271.	1.5	19
67	Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2019, 26, 3846-3855.	1.5	19
68	Benefit of regional anaesthesia on postoperative pain following mastectomy: the influence of catastrophising. <i>British Journal of Anaesthesia</i> , 2019, 123, e293-e302.	3.4	19
69	Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 667-677.	2.5	19
70	Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERBB3 alterations. <i>Modern Pathology</i> , 2020, 33, 1287-1297.	5.5	19
71	Clinico-pathologic predictors of patterns of residual disease following neoadjuvant chemotherapy for breast cancer. <i>Modern Pathology</i> , 2021, 34, 875-882.	5.5	18
72	Association of Local Therapy With Quality-of-Life Outcomes in Young Women With Breast Cancer. <i>JAMA Surgery</i> , 2021, 156, e213758.	4.3	18

#	ARTICLE	IF	CITATIONS
73	Implementation of a Venous Thromboembolism Prophylaxis Protocol Using the Caprini Risk Assessment Model in Patients Undergoing Mastectomy. <i>Annals of Surgical Oncology</i> , 2018, 25, 3548-3555.	1.5	17
74	Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 207-217.	2.5	17
75	Timeliness in Breast Cancer Treatment—The Sooner, the Better. <i>JAMA Oncology</i> , 2016, 2, 302.	7.1	16
76	Factors Affecting the Completion of Adjuvant Chemotherapy in Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 1537-1542.	1.5	16
77	Incorporating Patient-Reported Outcome Measures into Breast Surgical Oncology: Advancing Toward Value-Based Care. <i>Oncologist</i> , 2020, 25, 384-390.	3.7	16
78	Is Sentinel Lymph Node Biopsy Indicated at Completion Mastectomy for Ductal Carcinoma In Situ?. <i>Annals of Surgical Oncology</i> , 2016, 23, 2229-2234.	1.5	14
79	Implementation of Surgeon-Initiated Gene Expression Profile Testing (Oncotype DX) Among Patients With Early-Stage Breast Cancer to Reduce Delays in Chemotherapy Initiation. <i>Journal of Oncology Practice</i> , 2017, 13, e815-e820.	2.5	14
80	The Potential Impact of AMAROS on the Management of the Axilla in Patients with Clinical T1-2N0 Breast Cancer Undergoing Primary Total Mastectomy. <i>Annals of Surgical Oncology</i> , 2018, 25, 2612-2619.	1.5	14
81	The Landmark Series: Neoadjuvant Endocrine Therapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 3393-3401.	1.5	14
82	Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision. <i>Annals of Surgical Oncology</i> , 2022, 29, 1660-1667.	1.5	14
83	Impact of RxPONDER and monarchE on the Surgical Management of the Axilla in Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3361-3364.	1.6	14
84	Age and molecular subtypes: Impact on surgical decisions. <i>Journal of Surgical Oncology</i> , 2014, 110, 8-14.	1.7	13
85	Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 471-476.	1.5	13
86	Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution Series. <i>Annals of Surgical Oncology</i> , 2018, 25, 3527-3534.	1.5	13
87	Patient preferences for locoregional therapy in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 291-309.	2.5	13
88	Breast Cancer Surgical Risk Reduction for Patients With Inherited Mutations in Moderate Penetrance Genes. <i>JAMA Surgery</i> , 2018, 153, 1145.	4.3	12
89	Optimizing Axillary Management in Clinical T1-2N0 Mastectomy Patients with Positive Sentinel Lymph Nodes. <i>Annals of Surgical Oncology</i> , 2022, 29, 972-980.	1.5	12
90	Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come. <i>Annals of Surgical Oncology</i> , 2019, 26, 1173-1175.	1.5	11

#	ARTICLE	IF	CITATIONS
91	Racial and Socioeconomic Disparities in Breast Cancer Outcomes within the AJCC Pathologic Prognostic Staging System. <i>Annals of Surgical Oncology</i> , 2022, 29, 686-696.	1.5	11
92	Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 417-427.	2.5	11
93	Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experience. <i>Breast Journal</i> , 2020, 26, 384-390.	1.0	10
94	Do Body Mass Index and Breast Density Impact Cancer Risk Among Women with Lobular Carcinoma In Situ?. <i>Annals of Surgical Oncology</i> , 2020, 27, 1844-1851.	1.5	10
95	Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond. <i>Journal of the National Cancer Institute</i> , 2021, 113, 355-359.	6.3	10
96	Age, molecular subtypes and local therapy decision-making. <i>Breast</i> , 2017, 34, S70-S77.	2.2	9
97	Molecular determinants of post-mastectomy breast cancer recurrence. <i>Npj Breast Cancer</i> , 2018, 4, 34.	5.2	9
98	Limited Reporting of Histopathologic Details in a Multi-Institutional Academic Cohort of Phyllodes Tumors: Time for Standardization. <i>Annals of Surgical Oncology</i> , 2021, 28, 7404-7409.	1.5	9
99	Comparison of Outcomes for Classic-Type Lobular Carcinoma In Situ Managed with Surgical Excision After Core Biopsy Versus Observation. <i>Annals of Surgical Oncology</i> , 2022, 29, 1670-1679.	1.5	9
100	Selecting local therapy in the young breast cancer patient. <i>Journal of Surgical Oncology</i> , 2011, 103, 330-336.	1.7	8
101	Morbidity of local therapy for locally advanced metastatic breast cancer: an analysis of the Surveillance, Epidemiology, and End Results (SEER) Medicare Registry. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 287-293.	2.5	8
102	Triple-Negative Breast Cancer. <i>International Journal of Breast Cancer</i> , 2012, 2012, 1-1.	1.2	7
103	Optimal surgical management for high-risk populations. <i>Breast</i> , 2015, 24, S91-S95.	2.2	7
104	Trends and controversies in multidisciplinary care of the patient with breast cancer. <i>Current Problems in Surgery</i> , 2016, 53, 559-595.	1.1	7
105	Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 229-237.	2.5	7
106	Multidisciplinary considerations in the treatment of triple-negative breast cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 432-442.	329.8	7
107	The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 599-605.	2.5	7
108	Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer. <i>Oncology</i> , 2021, 35, 77-83.	0.5	7

#	ARTICLE	IF	CITATIONS
109	Arm Morbidity After Local Therapy for Young Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2021, 28, 6071-6082.	1.5	7
110	Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1744-1750.	6.3	7
111	Race and Site of Care Impact Treatment Delays in Older Women with Non-Metastatic Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 4103-4114.	1.5	7
112	Contralateral prophylactic mastectomy and quality of life: answering the unanswered questions?. <i>Gland Surgery</i> , 2016, 5, 261-262.	1.1	6
113	Comparative Analysis of Proposed Strategies for Incorporating Biologic Factors into Breast Cancer Staging. <i>Annals of Surgical Oncology</i> , 2020, 27, 2229-2237.	1.5	6
114	Tumor phenotype and concordance in synchronous bilateral breast cancer in young women. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 815-821.	2.5	6
115	Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 7347-7355.	1.5	6
116	How Often Does Retrieval of a Clipped Lymph Node Change Adjuvant Therapy Recommendations? A Prospective, Consecutive, Patient Cohort Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 3764-3771.	1.5	6
117	The effect of modifiable risk factors on breast cancer aggressiveness among black and white women. <i>American Journal of Surgery</i> , 2019, 218, 689-694.	1.8	5
118	Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors. <i>Annals of Surgical Oncology</i> , 2020, 27, 359-366.	1.5	5
119	Regional Nodal Management in Patients With Clinically Node-Negative Breast Cancer Undergoing Upfront Surgery. <i>Journal of Clinical Oncology</i> , 2020, 38, 2273-2280.	1.6	5
120	Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage III Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 7726-7736.	1.5	5
121	Prognostic impact of the 21-gene recurrence score in patients presenting with stage IV breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 507-507.	1.6	4
122	The Jacki Jacket after mastectomy with reconstruction: a randomized pilot study. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 377-385.	2.5	3
123	Incorporating the Results of the American College of Surgeons Oncology Group Z0011 Trial into Clinical Practice. <i>Current Breast Cancer Reports</i> , 2014, 6, 17-23.	1.0	2
124	Non-classic LCIS Versus Classic LCIS Versus Atypical Hyperplasia: Should Management be the Same?. <i>Current Surgery Reports</i> , 2018, 6, 1.	0.9	2
125	How do age and molecular subtypes impact surgical decisions?. <i>Breast Cancer Management</i> , 2018, 7, BMT04.	0.2	2
126	Statin Use and Breast Cancer Prognosis in Black and White Women. <i>Hormones and Cancer</i> , 2018, 9, 55-61.	4.9	2

#	ARTICLE	IF	CITATIONS
127	ASO Author Reflections: Tailoring Axillary Surgery After Neoadjuvant Endocrine Therapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1368-1369.	1.5	2
128	ASO Visual Abstract: Limited Reporting of Histopathologic Details in a Multi-Institutional Academic Cohort of Phyllodes Tumors: Time for Standardization. <i>Annals of Surgical Oncology</i> , 2021, 28, 465-466.	1.5	2
129	ASO Visual Abstract: Racial and Socioeconomic Disparities in Breast Cancer Outcomes within the AJCC Pathologic Prognostic Staging System. <i>Annals of Surgical Oncology</i> , 2021, 28, 585-586.	1.5	2
130	ASO Visual Abstract: Optimizing Axillary Management in Clinical T1â€“2N0 Mastectomy Patients with Positive Sentinel Lymph Nodes. <i>Annals of Surgical Oncology</i> , 2021, 28, 702-702.	1.5	2
131	Abstract P2-13-02: Pathologic nodal staging and systemic therapy among patients with cT1-2N0 HER2+ breast cancer: A prospective single institution cohort analysis. <i>Cancer Research</i> , 2022, 82, P2-13-02-P2-13-02.	0.9	2
132	Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes. <i>Annals of Surgical Oncology</i> , 2022, 29, 7674-7682.	1.5	2
133	Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS. <i>Annals of Surgical Oncology</i> , 2022, 29, 7696-7702.	1.5	2
134	New Insights on the Role of Surgery for the Breast Primary Tumor in Patients Presenting With Stage IV Disease. <i>Current Breast Cancer Reports</i> , 2017, 9, 137-147.	1.0	1
135	Variation in Deescalated Axillary Surgical Practices in Older Women with Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 4181-4194.	1.5	1
136	The prevalence and predictors of adjuvant chemotherapy use among patients treated with neoadjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 0, , .	2.5	1
137	Multifocality and Bilaterality of Lobular Carcinoma In Situ in Women with Synchronous Breast Malignancies. <i>American Journal of Clinical Pathology</i> , 2016, 146, .	0.7	0
138	Targeted Therapy and Local Control: The Dynamic Duo. <i>Annals of Surgical Oncology</i> , 2017, 24, 3110-3112.	1.5	0
139	Reply to L. Del Mastro and A. Prat. <i>Journal of Clinical Oncology</i> , 2017, 35, 1139-1139.	1.6	0
140	ASO Author Reflections: Breast Cancer Risk Assessment in Women with LCISâ€”More Work Is Needed. <i>Annals of Surgical Oncology</i> , 2020, 27, 741-742.	1.5	0
141	Reply to Comment on Margins in Breast-Conserving Surgery After Neoadjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 4053-4053.	1.5	0
142	ASO Visual Abstract: Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision. <i>Annals of Surgical Oncology</i> , 2022, 29, 1668-1669.	1.5	0
143	Abstract P3-18-05: Impact of neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) on breast tumor downsizing for patients with HER2+ breast cancer - results from a single-arm clinical trial. <i>Cancer Research</i> , 2022, 82, P3-18-05-P3-18-05.	0.9	0
144	Abstract P3-04-03: The value of screening MRI in patients with high-risk breast lesions: An observational single-institution cohort study. <i>Cancer Research</i> , 2022, 82, P3-04-03-P3-04-03.	0.9	0

#	ARTICLE	IF	CITATIONS
145	Abstract PD9-01: Expanding downstaging criteria in AJCC pathologic prognostic staging using OncotypeDx Recurrence Score® assay in T1-2N0 hormone-receptor positive patients enrolled in the TAILORx trial. <i>Cancer Research</i> , 2022, 82, PD9-01-PD9-01.	0.9	0
146	ASO Author Reflections: Is It Necessary to Routinely Clip and Localize the Biopsy-Proven Malignant Lymph Node?. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
147	ASO Visual Abstract: How Often Does Retrieval of a Clipped Lymph Node Change Adjuvant Therapy Recommendations? A Prospective Consecutive Patient Cohort Study. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
148	ASO Visual Abstract: Variation in Deescalated Axillary Surgical Practices in Older Women with Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
149	ASO Visual Abstract: Race and Site of Care Impact Treatment Delays for Older Women with Non-Metastatic Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, , .	1.5	0
150	Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ. <i>Breast Cancer Research and Treatment</i> , 2022, , .	2.5	0
151	Surgical Decision-making in Early-Stage Breast Cancer—Trends and Opportunities. <i>JAMA Surgery</i> , 0, , .	4.3	0